Renal Cancer Detection With Liquid Biopsy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZealand University Hospital
About this trial
Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.
Eligibility criteria
Qualifiers
Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
Sign up information consent
Can perform protocol procedure
Disqualifiers
Non-clear cell Renal cell carcinoma
RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
Trial design
Treatments tested in this trial
- GaGnostic
- GaGnostic
- GaGnostic
Treatment groups
200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov